Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (JPRN-jRCT2031250396) titled 'A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder' on Sept. 30.
Study Type: Interventional
Study Design:
randomized controlled trial, double blind, placebo control, parallel assignment, treatment purpose
Primary Sponsor: Takemura Kazuhiko
Condition:
Major Depressive Disorder
Intervention:
Vortioxetine:
Participants will receive the study drug, orally, once, daily (QD) for 14 weeks. The vortioxetine dose will be started at 10 mg per day, and can be increased to 20 mg per day.
Placebo:
Participants will receive the study drug, orally, once, daily (QD) for 14 weeks.......